Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 8/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079648 | 0.81 | PTGER1 (0.48) | PTGER1FOLH1NPC1MAPTRAB9A | |
| SCHEMBL6593178 | 0.81 | XDH (0.47) | XDHPTGER1FOLH1 | |
| SCHEMBL6080461 | 0.78 | FOLH1 (0.50) | PTGER1FOLH1NPC1MAPTRAB9A | |
| SCHEMBL6079919 | 0.76 | MAPT (0.41) | XDHNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6591653 | 0.75 | MRGPRX4 (0.46) | XDHPTGER1FOLH1 | |
| SCHEMBL6080114 | 0.75 | FFAR1 (0.38) | XDHPTGDR2 | |
| SCHEMBL6080232 | 0.74 | PTGER1 (0.43) | PTGER1FOLH1MAPTL3MBTL1 | |
| SCHEMBL6596273 | 0.72 | XDH (0.44) | XDHPTGER1PTGDR2 | |
| SCHEMBL6080444 | 0.71 | XDH (0.38) | XDHMAPT | |
| SCHEMBL6079841 | 0.71 | MMP2 (0.35) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | XDH 128/4885PTGER1 1819/4885FOLH1 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.